1 - 15 of 15

Paul Gadue, PhD

Paul Gadue

Dr. Gadue studies cell fate decisions, focusing on endoderm and mesoderm specification using human embryonic stem (ES) cells and induced pluripotent stem (iPS).


Kaila Gammon

Kaila Gammon

Establishes a set of definitions, policies, and procedures to guide the involvement of individuals such as long-term collaborators, high school and college-level students, graduate students, and others who are not regular CHOP employees in the Research Institute’s programs.


Lindsey A. George, MD

Lindsey A. George

Dr. George's basic and clinical research interests are in the development of novel therapeutics for hemophilia. Her basic science laboratory studies the molecular basis of coagulation, and she is the principal investigator of ongoing hemophilia A and B gene therapy trials.


Jill P. Ginsberg, MD

Jill P. Ginsberg

Dr. Ginsberg serves as director of the Cancer Survivorship Program at Children’s Hospital of Philadelphia and has a robust research program on survivorship and fertility preservation for cancer patients.


Kenneth R. Ginsburg, MD, MSEd

Kenneth R. Ginsburg

Dr. Ginsburg’s research focuses on facilitating youth to develop their own solutions to social problems and to teach clinicians how to better serve them. His current focus is on translating the best of what is known from research and practice into practical approaches parents, professionals, and communities can use to build resilience.


David J. Goldberg, MD

David J. Goldberg

Dr. Goldberg's research focuses on children with single ventricle congenital heart disease. Much of his work centers on the consequences of the abnormal single ventricle physiology and the impact on other organ systems throughout the body. He is also interested in medical interventions designed to improve the efficiency of the post-Fontan circulation by lowering pulmonary vascular resistance.


Samuel B. Goldfarb, MD

Samuel B. Goldfarb

Dr. Goldfarb has special interests in the treatment of children with end-stage lung disease such as cystic fibrosis, interstitial lung disease, pulmonary late effects of oncology treatments, and other pulmonary disorders.


Pedro Gonzalez-Alegre, MD, PhD

Dr. Gonzalez-Alegre’s long-range research goal is to advance the application of precision medicine in the neurology clinic. His research focus revolves around genetic disorders that affect the brain, spanning from the diagnosis of novel genetic disease in the clinic to the identification of novel molecular targets using disease models and the design of early-phase human clinical trials.

Dr. Gonzalez-Alegre's long-range research goal is to advance the application of precision medicine in the neurology clinic. His research focus revolves around genetic disorders that affect the brain, spanning from the diagnosis of novel genetic disease in the clinic to the identification of novel molecular targets using disease models and the design of early-phase human clinical trials.


Abby M. Green, MD

Abby M. Green

Dr. Green’s long-term goal is to elucidate the sources of DNA damage in childhood leukemia in order to develop better therapies and ultimately improve outcomes. She specifically studies the intersection of immune responses to viral infection and genome instability, working closely with virologists, oncologists, and geneticists at Children’s Hospital of Philadelphia, Penn, and nationwide.


Emily F. Gregory, MD, MHS

Emily F. Gregory

Dr. Gregory's overall career goal is to develop clinical programs to decrease rates of preterm birth. As a pediatric primary care physician-researcher, she seeks to leverage existing pediatric systems and opportunities for care to achieve this goal.


Andrew B. Grossman, MD

Andrew B. Grossman

Dr. Grossman is a pediatric gastroenterologist and co-director of Children's Hospital of Philadelphia’s Center for Pediatric Inflammatory Bowel Disease.


Stephan A. Grupp, MD, PhD

Stephan A. Grupp

Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.